Data / Drug companies / Teva Pharmaceuticals USA, Inc.
Teva Pharmaceuticals USA, Inc.: 382 products in the FDA NDC directory, labeler code 0093
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Teva Pharmaceuticals USA, Inc. (labeler code 0093) lists 382 products in the FDA National Drug Code Directory, covering 127 finished drugs by generic name. By type: 342 prescription drugs, 40 drugs for further processing. Its main marketing category is generic drugs (ANDA). The newest product started marketing on May 13, 2026.
The request: Watch Teva Pharmaceuticals USA, Inc. (FDA labeler code 0093): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0093
- Products in commercial distribution
- 382
- Packages
- 542
- Finished drugs by generic name
- 127
- Prescription products
- 342
- Over the counter products
- 0
- Controlled substance products
- Schedule II 8, Schedule III 5, Schedule IV 17
- Flagged as original packager
- 299 of 299 products that carry the flag
- Started marketing in the last 12 months
- 5
- Products with a marketing end date set
- 23
- Earliest marketing start
- May 1, 1984
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 317 | 83% |
| Drugs for further processing | 40 | 10.5% |
| Authorized generics (NDA) | 24 | 6.3% |
| Other unapproved drugs | 1 | 0.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 342 | 89.5% |
| Drugs for further processing | 40 | 10.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 115 | 30.1% |
| Tablet | 86 | 22.5% |
| Capsule | 57 | 14.9% |
| Capsule, extended release | 18 | 4.7% |
| Tablet, orally disintegrating | 14 | 3.7% |
| Powder, for suspension | 13 | 3.4% |
| Cream | 8 | 2.1% |
| Kit | 8 | 2.1% |
| Tablet, chewable | 8 | 2.1% |
| Injection | 6 | 1.6% |
| Solution | 6 | 1.6% |
| Tablet, film coated, extended release | 5 | 1.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Dapagliflozin | 0093-3528 | Tablet, film coated | Drugs for further processing | May 13, 2026 |
| Dapagliflozin | 0093-3527 | Tablet, film coated | Drugs for further processing | May 13, 2026 |
| Sitagliptin | 0093-2609 | Tablet, film coated | Drugs for further processing | March 13, 2026 |
| Sitagliptin | 0093-2608 | Tablet, film coated | Drugs for further processing | March 13, 2026 |
| Sitagliptin | 0093-2607 | Tablet, film coated | Drugs for further processing | March 13, 2026 |
| Ketorolac tromethamine | 0093-0314 | Tablet, film coated | Drugs for further processing | October 7, 2024 |
| Tramadol Hydrochloride | 0093-3301 | Tablet, film coated | Generic drugs (ANDA) | September 12, 2024 |
| Teriparatide | 0093-1106 | Injection, solution | Generic drugs (ANDA) | December 18, 2023 |
| Carbidopa and levodopa | 0093-9703 | Tablet | Generic drugs (ANDA) | December 15, 2023 |
| Glyburide | 0093-8035 | Tablet | Drugs for further processing | July 28, 2023 |
| Quinine sulfate | 0093-3002 | Capsule | Drugs for further processing | July 28, 2023 |
| Glyburide | 0093-8034 | Tablet | Drugs for further processing | July 27, 2023 |
| Famciclovir | 0093-8117 | Tablet, film coated | Drugs for further processing | June 23, 2023 |
| Nystatin | 0093-0983 | Tablet, film coated | Drugs for further processing | June 23, 2023 |
| Glyburide | 0093-8036 | Tablet | Drugs for further processing | June 22, 2023 |
| Famciclovir | 0093-8119 | Tablet, film coated | Drugs for further processing | May 5, 2023 |
| Famciclovir | 0093-8118 | Tablet, film coated | Drugs for further processing | May 5, 2023 |
| Mexiletine hydrochloride | 0093-8741 | Capsule | Drugs for further processing | March 30, 2023 |
| Mexiletine hydrochloride | 0093-8740 | Capsule | Drugs for further processing | March 30, 2023 |
| Mexiletine hydrochloride | 0093-8739 | Capsule | Drugs for further processing | March 30, 2023 |
| Cimetidine | 0093-8305 | Tablet, film coated | Drugs for further processing | March 30, 2023 |
| Cimetidine | 0093-8204 | Tablet, film coated | Drugs for further processing | March 30, 2023 |
| Cimetidine | 0093-8192 | Tablet, film coated | Drugs for further processing | March 30, 2023 |
| Doxepin hydrochloride | 0093-9609 | Cream | Generic drugs (ANDA) | February 17, 2023 |
| Sulfasalazine | 0093-3234 | Tablet | Generic drugs (ANDA) | December 15, 2022 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.